Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer

Oncology (Switzerland)

Volumn 87, Issue 1, 2014, Pages 30-39

  Kobayashi, Satoshi ^a   Ueno, Makoto ^a   Ohkawa, Shinichi ^a   Irie, Kuniyasu ^a   Goda, Yoshihiro ^a   Morimoto, Manabu ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Cholangiocellular carcinoma; Cisplatin; Creatinine; Glomerular filtration rate; Renal failure; Tolerability; Toxicity

Indexed keywords

CISPLATIN; CREATININE; GEMCITABINE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ASCITES; BILIARY TRACT CANCER; BILIARY TRACT DRAINAGE; BONE MARROW SUPPRESSION; CACNER FATIGUE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CONVERSION TO OPEN SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; LIVER ABSCESS; LUNG INTERSTITIAL; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OVERALL SURVIVAL; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SENSORY NEUROPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; EXTRACELLULAR FLUID; FATIGUE; FOLLOW UP; KIDNEY DISEASE; NAUSEA; NEUROPATHY; SIDE EFFECT; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84902949517     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000362604     Document Type: Review

References (46)

1. Matsuda T, Marugame T: International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII. Jpn J Clin Oncol 2007; 37: 74-75.
2. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T: Phase II study of singleagent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57: 647-653.
3. Verderame F, Mandina P, Abruzzo F, Scarpulla M, Di Leo R: Biliary tract cancer: Our experience with gemcitabine treatment. Anticancer Drugs 2000; 11: 707-708.
4. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T: A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37: 843-851.
5. Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A: Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: An analysis of 100 cases. Oncology 2010; 79: 39-45.
6. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
7. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y: Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474.
8. Kameda R, Ando T, Kobayashi S, Ueno M, Ohkawa S: A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer. Jpn J Clin Oncol 2013; 43: 636-640.
9. Zwelling LA, Kohn KW: Mechanism of action of cis- dichlorodiammineplatinum(II). Cancer Treat Rep 1979; 63: 1439-1444.
10. Drobnik J, Horacek P: Specific biological activity of platinum complexes. Contribution to the theory of molecular mechanism. Chem Biol Interact 1973; 7: 223-229.
11. Talley RW, O'Bryan RM, Gutterman JU, Brownlee RW, McCredie KB: Clinical evaluation of toxic effects of cisdiamminedichloroplatinum (nsc-119875)-phase I clinical study. Cancer Chemother Rep 1973; 57: 465-471.
12. Mollman JE: Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126-127.
13. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R: Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997; 40: 293-308.
14. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
15. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
16. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P: Cisplatin neuropathy: Clinical course and neurophysiological findings. J Neurol 1992; 239: 199-204.
17. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992; 69: 203-207.
18. Legha SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J Clin Oncol 1985; 3: 1373-1378.
19. Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: A review. Am J Med Sci 2007; 334: 115-124.
20. Hanigan MH, Devarajan P: Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther 2003; 1: 47-61.
21. Willox JC, McAllister EJ, Sangster G, Kaye SB: Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: A randomised trial. Br J Cancer 1986; 54: 19-23.
22. Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcislo K, Szczylik C: Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study. Eur J Cancer 2008; 44: 2608-2614.
23. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18: 1921-1927.
24. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 1999; 17: 2876-2881.
25. Raftopoulos H, et al: Assessing the role of cisplatin dose and dose intensity in advanced non-small lung cancer: A comprehensive review of randomized trials 1992-2002 (abstract). Proc Am Soc Clin Oncol 2003; 22: 2596.
26. Lippe P, Tummarello D, Monterubbianesi MC, Silva RR, Giuliodori L, Mari D, Santo A, Pasini F, Cetto GL, Rossi D, Porfiri E, Cascinu S, Cellerino R: Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. Ann Oncol 1999; 10: 217-221.
27. Berardi R, Porfiri E, Scartozzi M, Lippe P, Silva RR, Nacciarriti D, Menichetti ET, Tummarello D, Carle F, Piga A, Cellerino R: Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 2003; 65: 198-203.
28. Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ, Song HH, Lee KS, Zang DY, Ahn JS, Park YL, Lee JA: A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54: 57-62.
29. Hussain SA, Palmer DH, Swinson DE, Riley P, Wills A, Brown C, Draycott C, El-Modir A, Peake DR, Rea DW, Chetiyawardana AD, Cullen MH: A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. Oncol Rep 2008; 20: 233-237.
30. Hiramatsu A, Iwasaki Y, Koyama Y, Tamiya N, Hosogi S, Nakanishi M, Kohno Y, Ueda M, Arimoto T, Marunaka Y: Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer. Jpn J Clin Oncol 2009; 39: 779-783.
31. Hussain SA, Palmer DH, Lloyd B, Collins SI, Barton D, Ansari J, James ND: A study of split-dose cisplatin-based neo-Adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 2012; 3: 855-859.
32. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
34. Lippman AJ, Helson C, Helson L, Krakoff IH: Clinical trials of cis-diamminedichloroplatinum (nsc-119875). Cancer Chemother Rep 1973; 57: 191-200.
35. Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ: Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabinepretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009; 32: 348-352.
36. Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, Ruggeri EM, Carlini P, Cognetti F: Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009; 76: 254-261.
37. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T: Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. Lancet Oncol 2010; 11: 1142-1148.
38. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012; 30: 708-713.
39. Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J: A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 2013; 71: 1141-1146.
40. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91: 1769-1774.
41. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 2002; 50: 25-32.
42. Krarup-Hansen A, Rietz B, Krarup C, Heydorn K, Rorth M, Schmalbruch H: Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: An autopsy study. Neuropathol Appl Neurobiol 1999; 25: 29-40.
43. Gill JS, Windebank AJ: Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998; 101: 2842-2850.
44. van der Hoop RG, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FG, Gispen WH, et al: Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94.
45. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F: Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol 1990; 25: 355-360.
46. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C: Neuronal involvement in cisplatin neuropathy: Prospective clinical and neurophysiological studies. Brain 2007; 130: 1076-1088.